昭衍新药(06127)前三季度归母净利润8070.61万元 同比扭亏为盈

Core Viewpoint - Zhaoyan New Drug (06127) reported a significant decrease in revenue for the first three quarters of 2025, while achieving a positive net profit compared to a loss in the same period last year [1] Financial Performance - The company achieved an operating revenue of 985 million yuan, representing a year-on-year decrease of 26.23% [1] - The net profit attributable to the parent company was 80.7061 million yuan, a turnaround from a loss of 70.3071 million yuan in the same period last year [1] - Basic earnings per share were reported at 0.11 yuan [1]